|

FDC fianlimab+cemiplimab Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Libtayo, REGN2810, REGN3767

Pipeline

Phase 2: 1

Top Sponsors

  • Regeneron Pharmaceuticals1

Indications

  • Head and Neck Squamous Cell Carcinoma (HNSCC)1
  • Cancer1

Omaha, Nebraska1 trial

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Oncology Hematology West P.C. dba Nebraska Cancer Specialists

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.